Egypt International Pharmaceuticals operates within the Pharmaceutical preparations sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Egypt International Pharmaceuticals with three other
pharmaceutical manufacturers in Middle East:
Dar Al Dawa Development & Investment
sales of 60.88 million Jordanian Dinars [US$85.86 million]
of which 80%
(182.39 million Israel Shekels [US$51.77 million]
of which 104%
was Nutrition), and
Glaxo Smith Kline
(1.17 billion Egyptian Pounds [US$65.21 million]
of which 93%
was Medical Sector).
During the year ended December of 2016, sales at
Egypt International Pharmaceuticals were 1.97 billion Egyptian Pounds (US$110.15 million).
increase of 16.0%
versus 2015, when the company's sales were 1.70 billion Egyptian Pounds.
This was the fifth consecutive year of sales increases at Egypt International Pharmaceuticals
(and since 2011, sales have increased a total of 69%).